Logo
APAC Active Pharmaceutical Ingredients (API) Market 2021-2028

APAC Active Pharmaceutical Ingredients (API) Market 2021-2028

Bonafide Trust 03-04-2022 192 Pages
Region : Asia-Pacific Category : Lifescience Pharmaceutical

Asia Pacific active pharmaceutical ingredients market will grow by 8.8% annually with a total addressable market cap of $691.3 billion over 2021-2028, driven by rising adoption of biologics in disease management, increasing regulatory approvals, patent expiration of major drugs, growing trend of outsourcing and increase in geriatric population. Highlighted with 92 tables and 68 figures, this 192-page report “Asia Pacific Active Pharmaceutical Ingredients (API) Market 2021-2028 by Synthesis (Synthetic, Biotech, HPAPI), Manufacturing Process (Captive, Merchant), Therapeutic Application, Drug Type, and Country: Trend Forecast and Growth Opportunity” is based on comprehensive research of the entire Asia Pacific active pharmaceutical ingredients market and all its sub-segments through extensively detailed classifications. Profound analysis and assessment are generated from premium primary and secondary information sources with inputs derived from industry professionals across the value chain. The report is based on studies on 2018-2021 and provides forecast from 2022 till 2028 with 2021 as the base year. (Please note: The report will be updated before delivery so that the latest historical year is the base year and the forecast covers at least 5 years over the base year.) In-depth qualitative analyses include identification and investigation of the following aspects: • Market Structure • Growth Drivers • Restraints and Challenges • Emerging Product Trends & Market Opportunities • Porter’s Fiver Forces The trend and outlook of Asia Pacific market is forecast in optimistic, balanced, and conservative view by taking into account of COVID-19. The balanced (most likely) projection is used to quantify Asia Pacific active pharmaceutical ingredients market in every aspect of the classification from perspectives of Synthesis, Manufacturing Process, Therapeutic Application, Drug Type, and Country. Based on Synthesis, the Asia Pacific market is segmented into the following sub-markets with annual revenue ($ bn) for 2018-2028 included in each section. Synthetic API • Branded Synthetic API • Generic Synthetic API Biotech API by Drug Type: • Monoclonal Antibodies • Recombinant Proteins • Vaccines • Other Biotech APIs Biotech API by Customer Base: • Innovative Biologic API • Generic Biosimilar API Biotech API by Expression Technology: • Mammalian Expression • Microbial Expression • Yeast Expression • Insect Expression • Other Expression Technologies HPAPI • Branded HPAPI • Generic HPAPI Based on Manufacturing Process, the Asia Pacific market is segmented into the following sub-markets with annual revenue ($ bn) for 2018-2028 included in each section. Captive Manufacturing • Branded Captive API • Generic Captive API Merchant Manufacturing by Drug Type: • Branded Merchant API • Generic Merchant API Merchant Manufacturing by Drug Synthesis: • Merchant Synthetic API • Merchant Biotech API By Therapeutic Application, the Asia Pacific market is segmented into the following sub-markets with annual revenue ($ bn) for 2018-2028 included in each section. • Infectious Diseases • Oncology • Ophthalmology • Cardiovascular Disorders • Central Nervous System • Pulmonary Disorders • Orthopedics • Other Applications By Drug Type, the Asia Pacific market is segmented into the following sub-markets with annual revenue ($ bn) for 2018-2028 included in each section. • Branded Prescription Drugs • Generic Prescription Drugs • OTC Drugs Geographically, the following national/local markets are fully investigated:UK • Japan • China • South Korea • Australia • India • Rest of APAC (further segmented into Malaysia, Singapore, Indonesia, Thailand, New Zealand, Vietnam, Taiwan, and Philippines) For each key country, detailed analysis and data for annual revenue ($ bn) are available for 2018-2028. The breakdown of key national markets by Synthesis, Manufacturing Process, and Therapeutic Application, over the forecast years are also included. The report also covers current competitive scenario and the predicted trend; and profiles key vendors including market leaders and important emerging players. Selected Key Players: AbbVie Inc. Astrazeneca Aurobindo Pharma Ltd. BASF Bayer AG Boehringer Ingelheim Catalent Inc. Dr. Reddy's Laboratories F. Hoffmann-La Roche GlaxoSmithKline plc Lonza Group Lupin Limited Merck & Co., Inc. Mylan NV Novartis International AG Pfizer Inc. Sanofi Sun Pharmaceutical Industries Ltd. Teva Pharmaceutical Industries Ltd. Thermo Fisher Scientific (Please note: The report will be updated before delivery so that the latest historical year is the base year and the forecast covers at least 5 years over the base year.)

Read More

Card image cap

Interested in this report?
Get your FREE sample!

Requirement Gathering & Methodology
Data Collection Techniques
Our Research Team & Data Sourcing
Data Science & Analytical Tools
Data Visualization & Presentation Skills
Project/ Report Delivery & After Sales Services